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It is not known whether increased breast cancer risk caused by menopausal hormone 
therapy (HT) depends on body mass patterns through life. In a prospective study of 
483,241 Norwegian women aged 50-69 years at baseline, 7,656 women developed 
breast cancer during follow-up (2006-2013). We combined baseline information on 
recalled body mass in childhood/adolescence and current (baseline) body mass index 
(BMI) to construct mutually exclusive life-course body mass patterns. We assessed 
associations of current HT use with breast cancer risk according to baseline BMI and 
life-course patterns of body mass, and estimated relative excess risk due to interaction 
(RERI). Within all levels of baseline BMI, HT use was associated with increased risk. 
Considering life-course body mass patterns as a single exposure, we used women who 
“remained at normal weight” through life as the reference, and found that being 
“overweight as young” was associated with lower risk (hazard ratio (HR) 0.85, 95% 
confidence interval (CI) 0.76-0.94), whereas women who “gained weight” had higher 
risk (HR 1.20, 95% CI 1.12-1.28). Compared to never users of HT who were 
“overweight as young”, HT users who either “remained at normal weight” or “gained 
weight” in adulthood were at higher risk than expected when adding the separate risks 
(RERI 0.52, 95% CI 0.09-0.95, and RERI 0.37, 95% CI -0.07-0.80), suggesting effect 
modification. Thus, we found that women who remain at normal weight or gain 
weight in adulthood may be more susceptible to the risk increasing effect of HT 
compared to women who were overweight as young. 
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The use of hormone therapy (HT) around menopause, particularly estrogen 
and progestogen in combination (EPT), increases the risk of breast cancer [1, 2]. 
Ideally, an individual risk-benefit assessment should be performed before prescribing 
HT for menopausal symptoms [3], but predicting individual breast cancer risk is 
difficult and has its limitations [3, 4]. One challenge is that the effect of HT use may 
be modified by other factors that influence risk [5-8]. Previously, it has been 
suggested that the risk increasing effect of HT is weaker in overweight than in normal 
weight women [1, 7, 9, 10], and that HT use may not contribute to additional risk in 
women who are overweight around menopause [5, 6]. However, in most previous 
studies, relative risks were compared directly between subgroups with different 
baseline risk, an approach that may not be appropriate to assess the importance of 
effect modification [11]. Instead, for public health purposes and in individual 
decision-making, the additive scale is preferable [12], where positive departure from 
additivity implies that the number of cases attributable to the combination of risk 
factors exceed the sum of cases attributable to each individual risk factor [13]. It is 
well known that overweight after menopause is positively associated with breast 
cancer risk [14-16], whereas overweight at younger ages is inversely associated with 
risk before menopause [15, 17]. In addition, there is accumulating evidence that 
overweight in childhood and adolescence is inversely associated with risk, both 
before and after menopause [15, 16, 18-24].  
Thus, the complex role of body mass warrants closer examination of the 
combined effects of HT and body mass on breast cancer risk. If the effect of HT 
varies according to life course patterns of body mass, tailored recommendations for 
HT use may be a relevant option. Therefore, we studied body mass patterns from 
childhood until postmenopausal age, and assessed whether the association of HT use 
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The source of the study population was women who attended the Norwegian Breast 
Cancer Screening Program [25], to which all women 50 to 69 years of age with 
residence in Norway receive biennial invitations (for practical purposes, age at 
invitations ranges from 48 to 71 years). The program reached national coverage in 
2005, and at each round, attendance has been stable at approximately 75%. Among all 
invited women, 84% participate at least once [25].  
In the period 2006-2015, questionnaires were included with the invitations 
[26], and completion of the first questionnaire was defined as the baseline from when 
each woman was followed up for breast cancer. In addition to socio-demographic 
factors, the questionnaires covered age at menarche, use of hormonal contraception, 
age at first birth, number of pregnancies, information on smoking habits (never, 
former, current), and alcohol consumption. Information about current and previous 
health was included, as well as BMI at the time of participation (termed baseline BMI 
from here) [10]. The women were also asked to categorize their height and weight 
relative to their peers in childhood (age 7 years) and adolescence (age 15 years). 
These ages were selected to cover the period before and after age at menarche, which 
is an established breast cancer risk factor [27, 28]. Age 7 and 15 years correspond to 
the ages when women in the cohort started school and had their Christian 
confirmation ceremony, respectively, possibly improving recall accuracy.  
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Using the 11-digit personal identification number of Norwegian residents, we 
linked questionnaire data to information about all incident cases of invasive breast 
cancer registered at the Cancer Registry of Norway (International Classification of 
Diseases, 7th edition) [29], and to information on date of death and emigration from 
the Central Population Registry. Follow-up started at questionnaire completion (first 
attendance in the screening program after January 1, 2006), and ended at the date of 
breast cancer diagnosis, date of emigration, date of death from other causes than 
breast cancer, or at the end of follow-up, December 31, 2013, whichever occurred 
first. 
A total of 488,112 women responded (86% of all screened women) [30]. 
Among them, we excluded 4,853 women with previously diagnosed breast cancer and 
18 women who had emigrated or died within a month after screening participation. 
Thus, 483,241 women were followed up for incident breast cancer and included in the 
analyses.   
The study was approved by the Regional Committee for Ethics in Medical 
Research in Norway (reference no. 2014/1711 REK south-east D). 
Study variables 
In the questionnaire, the participants were asked to categorize their body weight 
compared to their peers at the ages of 7 and 15 years as being “much below average”, 
“somewhat below average”, “average”, “somewhat above average”, or “much above 
average”. Due to few responses in the most extreme categories, we combined the 
responses at each age into “below average”, “average” or “above average”. 
We used these categories in combination with baseline BMI to construct three 
life course patterns of body mass. We considered the results for weight in childhood 
and adolescence as sufficiently consistent to combine them into a single measure 
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(correlation coefficient 0.62), thereby reducing loss of power from missing values on 
one of the questions. Thus, we classified women who reported weight above average 
at either 7 or 15 years as being “overweight as young”, regardless of their baseline 
BMI. This decision was supported by previous publications that show negative 
associations of similar strength for overweight at different ages early in life with 
breast cancer risk before and after menopause, independently of adult BMI [18]. 
Women who reported weight below or at average at 7 and 15 years of age (or at a 
single age if missing on the other age), and whose BMI was <25 kg/m² at baseline, 
were classified as “remained at normal weight” through life. Finally, women who 
reported weight below or at average at 7 and 15 years of age, but were overweight 
(BMI ≥25 kg/m²) at baseline, were classified as having “gained weight”.  
We excluded women who reported menarche before 8 or after 18 years of age 
[27], first pregnancy before 8 or after 55 years of age, baseline body weight less than 
30 kg or more than 299 kg, or height less than 120 cm or more than 203 cm, from 
analyses of these factors, respectively. In analyses of age at natural menopause, 
women with a surgical menopause (i.e. hysterectomy and/or uni- or bilateral 
oophorectomy), or menopause before 15 or after 71 years of age (the oldest 
participant), were excluded [31, 32]. 
 The questions about current and former use and duration of HT use indicated 
use of the following HT-formulations: estradiol-NETA (oral formulations: Kliogest, 
Activelle, Trisekvens, Novofem, and transdermal formulations: Sequidot, Estalis), 
estradiol-medroxyprogesterone (Indivina), estradiol-levonorgestrel (Cyclabil), tibolon 
(Livial), estriol (Ovesterin) and estradiol (Progynova (oral), Estradot and Evorel 
(transdermal)). In the analyses, we restricted HT use to systemic therapy in broad 
categories; either all types of HT or, more specifically, use of EPT. Among current 
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users of HT, 11% reported <2 years of use, 13% 2-5 years, 18% 5-10 years, and 31% 
≥10 years, whereas 27% did not report duration of use. 
Statistical analyses 
Cox proportional hazards models were used to estimate associations (hazard ratios, 
HRs, with 95% confidence intervals, CIs) of single exposures, as well as the 
combination of exposures, with breast cancer risk. In all models, attained age was 
used as the timescale. Departure from the proportional hazards assumption was 
evaluated by Schoenfeld residuals and by inspection of the log-log plots.    
 We assessed whether the association of all types of HT (or specifically, EPT) 
with breast cancer risk could be modified by body mass. Thus, we assessed effect 
modification of HT by baseline BMI and by life course patterns of body mass, and 
considered effect modification as present if the risk associated with both exposures 
departed from additivity [33, 34]. Thus, relative excess risk due to interaction (RERI) 
[35-37] was calculated as HR11-HR10-HR01+HR00 where HRij is the hazard ratio for i 
= use of HT (0 = never, 1 = current) and j = BMI (0 = <25, 1 = ≥25) or weight/body 
mass pattern (0 = “overweight as young”, 1 = “remained at normal weight” or 1 = 
“gained weight”). RERI corresponds to the excess risk due to effect modification, 
expressed as a proportion of the hazard in women who are free from both risk factors. 
The null-value of RERI, corresponding to additivity of risks, is zero. 
HT use was the factor of primary interest, and therefore, we assessed potential 
confounding by factors associated with both HT use and breast cancer risk, according 
to recent recommendations [34]. Thus, we adjusted for the following potentially 
confounding factors: education (<9, 9, 12, >12 years), age at first birth (<20, 20-24, 
25-29, 30-34, ≥35 years, nulliparous), number of children (0, 1, 2, 3, 4-14) and 
current alcohol consumption (abstainer, 1-5, 6-10, >10 units per month). In analyses 
	 9	
including relative weight in childhood or adolescence, we also adjusted for relative 
height at age 7 or 15 years (below average, average, above average) to account for 
variation in relative weight due to variation in height. Women with missing data on 
specific factors were excluded from the analyses where these factors were included as 
either exposures or as covariates. 
In sensitivity analyses, we excluded 2,206 cases diagnosed within six months 
after start of follow-up to address potential bias from reverse causality (i.e. detection 
of advanced breast cancers that might have affected body weight at baseline). We also 
repeated analyses with body mass at younger ages based on the individual responses 
at age 7 and 15 years, rather than the combination of these two. 
Other studies have evaluated effect modification of HT by BMI on a 
multiplicative scale [5, 6, 10]. To enable comparison with these studies, we also 
applied a multiplicative scale, and used likelihood-ratio tests to assess effect 
modification [38]. Some studies included data that allowed calculation of RERI, but 
did not present estimates of RERI. We therefore calculated RERI from these studies, 
using the formula referred to above [38, 39]. In these studies, only postmenopausal 
women were included in the analyses. To facilitate comparison, we therefore repeated 
our own analyses of effect modification according to baseline BMI for women <55 
and ≥55 years, using age ≥55 years at baseline to approximate postmenopausal status. 
All analyses were performed using the statistical software Stata (Version 13.1; Stata 
Corp, College Station, TX, USA). 
RESULTS 
During 2,432,832 person-years, 7,656 incident cases of invasive breast cancer were 
diagnosed. Mean age at baseline was 57.0 years, and mean age at diagnosis was 61.0 
years (range 48.6 to 76.7 years). Mean duration of follow-up was 5.0 years (median 
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5.8 years). Among cases, 44.5% (3,406) were stage I at diagnosis; 20.9% (1,601) 
were stage II; 3.2% (246) were stage III, 1.1% (82) were stage IV; 0.6% (47) were 
stage 0 (carcinoma in situ), and 29.7% (2,274) had unknown stage at the time of 
diagnosis.  
Table 1 summarizes age-adjusted associations of well-known risk factors for 
breast cancer (age at menarche, age at first birth, parity, number of children, age at 
natural menopause), and shows that the results were all in the expected directions. 
Only 13% of participants reported that they still had menstrual cycles, whereas 6% 
were unsure and/or had irregular cycles. Among women who had never used HT, the 
corresponding percentages were 19% and 9%, respectively. The correlation 
coefficient between HT use and baseline BMI was -0.03, and 11% of women with 
BMI ≥25 kg/m2 were current users of HT compared to 13% of women with BMI <25 
kg/m2. 
Body mass patterns through life and use of HT as single exposures 
Self-reported weight at 7 and 15 years of age were both inversely associated with 
breast cancer risk later in life (Table 2), whereas baseline BMI was positively 
associated with risk. The association of baseline BMI with breast cancer was 
somewhat stronger for women who were postmenopausal or ≥55 years at baseline, 
compared to women who were premenopausal or <55 years (Online Resource 1).  
In the analysis of body mass patterns through the life course, we used women 
who had “remained at normal weight” as the reference, and found a lower risk of 
breast cancer in women who were “overweight as young” (HR 0.88, 95% CI 0.80-
0.97). On the other hand, women who had “gained weight”  (average or less at 7 
and/or 15 years, but overweight between 50 and 69 years of age) were at higher risk 
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(HR 1.15, 95% CI 1.08-1.23) compared to women who had “remained at normal 
weight” through life.  
Current use of HT was associated with a strong increase in risk. Thus, risk in 
current users was nearly two-fold (HR 1.92, 95% CI 1.80-2.05) compared to never 
users. The medication was dominated by EPT, and for current EPT users, the risk was 
slightly higher than for all HT users (HR 2.22, 95% CI 2.07-2.38), compared to never 
users (Table 2). 
 
Effect modification of HT use related to baseline body mass and body-mass 
patterns through life 
Table 3 shows effect modification of HT use by baseline BMI. Women who were 
either current users of HT (HR 2.09, 95% CI 1.90-2.30) or whose baseline BMI was 
≥25 kg/m2 (HR 1.20, 95% CI 1.11-1.29), had a higher risk of breast cancer compared 
to never users of HT whose BMI was <25 kg/m2. The risk in women with both 
exposures (current HT use and overweight) was roughly the same as expected when 
adding the risks associated with each factor (RERI -0.11, 95% CI -0.37-0.15). Thus, 
the association of HT use with breast cancer risk did not appear to be modified by 
baseline BMI. 
In Tables 4 and 5 and in Figure 1, we present effect modification of HT use by 
body mass patterns through life, with the combination of never use of HT and 
“overweight as young” as the common reference.  We found that current HT users 
who were “overweight as young”, were at higher risk (HR 1.68, 95% CI 1.32-2.14) 
compared to never users of HT who were “overweight as young”. However, we found 
the highest risk in current HT users who had “remained at normal weight” (HR 2.25, 
95% CI 1.93-2.62). Their risk was higher than expected when adding the risks 
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associated with each of the two factors (RERI 0.52, 95% CI 0.09-0.95), suggesting 
effect modification. Similarly (Table 5), the combination of current HT user and 
“gained weight” in adulthood (HR 2.28, 95% CI 1.94-2.67), also indicated effect 
modification (RERI 0.37, 95% CI -0.07-0.80). 
In separate analyses, applying a method often used by other investigators, we 
tested whether HT use and body mass were associated with departure from 
multiplicativity of effects on breast cancer risk, using likelihood ratio tests. Thus, we 
found that hazard ratios of breast cancer for HT use differed between baseline BMI 
≥25 kg/m2 versus <25 kg/m2, suggesting that associations were less than 
multiplicative (likelihood-ratio test P = 0.04). For the pattern “remained at normal 
weight” versus “overweight as young”, departure from multiplicativity was less 
convincing (P = 0.07), and for “gained weight” versus “overweight as young”, there 
were no indications of departure from multiplicativity(P = 0.54).  
 The results for any use of HT and results restricted to use of EPT were nearly 
identical. Also, including adjustment for potentially confounding factors (Online 
Resources 2-4), the multivariable-adjusted estimates did not substantially differ from 
the age-adjusted results.  
In sensitivity analysis, we excluded 2,206 cases detected within six months of 
the study baseline, but the results were nearly identical to the main results.  Results 
were also similar when using weight only at age 7 years or only at age 15 years, 
instead of the combination of these, to define “overweight as young”. We also 
compared women with and without missing information on body weight at 7 and/or 
15 years of age, and found that baseline BMI was practically identical (25.9 kg/m² 
and 25.8 kg/m²).  
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In Online Resource 5, we use data available from previous studies, and present 
RERI as calculated from information about HT use and current BMI or weight gain, 
using a common reference category [15, 40-46]. Estimates of RERI varied greatly 
between studies, but were <0 in all except for one case-control study [41], suggesting 
possible effect modification on the additive scale in nearly all studies. In separate 
analyses according to age at baseline in the present cohort, RERI was -0.06 (95% CI 
0.46-0.34) for women <55 years and -0.24 (95% CI -0.59-0.11) for women ≥55 years 
at baseline (Online Resource 6 and 7). 
DISCUSSION 
In this large population based study with follow-up for breast cancer among ever 
attendees in the Norwegian Breast Cancer Screening Program, we found that HT use 
was associated with increased breast cancer risk within all levels of baseline BMI. 
The results also suggest that the effect of HT may be modified by body mass patterns 
through life; thus, the excess risk associated with HT use was substantially higher in 
women who either remained at normal weight or gained weight in adulthood, 
compared to women who were overweight at a young age.  
Major strengths of our study include the large population of women from all 
parts of Norway, complete follow-up for breast cancer incidence and total mortality, 
and high validity of the diagnoses recorded in the Cancer Registry of Norway [29].  
HT use increased steeply in Norway in the 1990s, peaked around 2000 and 
decreased after the results from the Women’s Health Initiative were published [47]. 
Since breast cancer follow-up in this study started in 2006, HT use among participants 
was essentially restricted to women with severe menopausal symptoms, and the 
estrogen content of the medication was lower than in the 1990s [47]. We compared 
HT use in our study population to data on dispensed prescriptions from the 
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Norwegian Prescription Database, and found that nationally, 6.6% in the relevant age 
group were current users of EPT in 2010. This corresponds well with the 6.4% of EPT 
users in our study population and suggests that HT use in this study is comparable to 
HT use in the background population, despite the fact that only women attending 
mammography screening were included in this study. In a study that compared 
women who did and did not attend the NBCSP during the period 2002-2007, self-
reported BMI was similar for attenders and non-attenders [48]. However, we cannot 
exclude the possibility that the participants may differ from the background 
population with respect to other factors that are associated with breast cancer risk, or 
that the associations observed may differ from those in a non-screened population.  
BMI may predict menopausal symptoms, and a high current BMI may indicate a 
lower need for HT around menopause [49]. However, the weak correlation between 
baseline BMI and HT use in our study suggests that the two factors may be regarded 
as independent. 
We had information on established risk factors for breast cancer, and it is 
important to note that adjustment for potential confounding by these factors did not 
materially influence the results. Self-reported information has some limitations, and 
recall of body weight at 7 and 15 years of age is vulnerable to misclassification. 
However, studies of other cohorts suggest that agreement between recall and 
objective measurements of body size is fairly good, and recalled comparisons with 
body size of peers at the same age appear to be reliable [50]. Still, constructing life-
course patterns of body mass from two time-points is not likely to capture all relevant 
weight changes.  
Our results confirm that overweight at a young age, indicated by self-reported 
weight at 7 or 15 years of age, is associated with a relative reduction in breast cancer 
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risk later in life. Similar findings have been reported by others [15, 16, 18-23, 51]. In 
addition, our findings suggest that HT use is associated with higher risk also in 
women who were overweight at a young age, but the association appears to be less 
pronounced than in HT users who either remained at normal weight through life or 
became overweight or obese as adults. Although plausible explanations may be 
difficult to identify, the lower breast density that has been observed in women who 
were overweight at a young age, may provide some clues [52-54]. It is also known 
that menopausal HT use increases breast density [55-57], and it seems conceivable 
that breast density may be of importance, both for the reduced risk of breast cancer 
associated with overweight at a young age, and for the increased risk associated with 
menopausal HT [58]. The relations of HT use, BMI and breast density are complex, 
and for example, the positive association of breast density with mammographic 
sensitivity may influence breast cancer detection [57].  
It is well established that HT use is more strongly associated with hormone 
receptor positive breast cancer [10], whereas overweight at a young age may confer a 
lower risk for all breast cancer subtypes [23]. Unfortunately, detailed information 
about breast cancer subtypes was not available to us, but we acknowledge that an 
effect modification of HT by life-course body mass patterns, may be more relevant 
for some than for other subtypes of breast cancer.  
The multiplicative scale is often used to assess potential effect modification, 
but the additive scale is preferable in situations where the excess number of cases due 
to the combination of exposures is of interest [11-13, 59]. We found that associations 
of HT use and baseline BMI were approximately additive (i.e. less than 
multiplicative), corresponding to a similar increase in absolute risk associated with 
HT use in both categories of baseline BMI. For HT use and life-course body mass 
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patterns, associations were more than additive, corresponding to a larger increase in 
absolute risk associated with HT use among women who either remained at normal 
weight or gained weight, compared to women who were overweight at a young age.  
For women who remained at normal weight, the associations were more than 
multiplicative, whereas for women who gained weight, the associations were 
approximately multiplicative. 
In most previous studies of HT use and breast cancer risk, information on BMI 
was restricted to adult or current BMI, and effect modification was assessed on a 
multiplicative scale [1, 5-10, 60-75]. Two studies, using the additive scale, have 
quantified effect modification of HT use by current BMI [45, 76], but found no clear 
evidence for effect modification. Our results related to baseline BMI are consistent 
with those findings.  
However, when applying an additive scale on results from previous studies of 
postmenopausal women [15, 40-46], we found some indication that the effect of HT 
use could be modified (i.e. weakened) by current BMI (RERIs from all but one study 
were negative). Our results for baseline BMI in mainly postmenopausal women (≥55 
years) are in line with these results. However, it is important to note that a negative 
RERI does not in itself imply that HT can be used without further increasing breast 
cancer risk in overweight or obese women. 
In summary, we found that HT use around menopause is associated with 
increased risk of breast cancer regardless of baseline BMI. However, women who 
were overweight at a young age had a lower excess risk associated with HT use 
compared to women who had either remained at normal weight or gained weight as 
adults. The two latter groups had the highest excess risk of breast cancer associated 
with HT, suggesting that these women may be more susceptible to the risk increasing 
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effect of HT use, and that particular care should be taken when considering the 
balance between relieving menopausal symptoms and breast cancer risk in these 
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Effect modification of breast cancer risk related to use of HT and the life-course body 
mass patterns “remained at normal weight” versus “overweight as young” Among 
468,736 Norwegian Women 2006-2013 
 
  
RERI (relative excess risk due to interaction) equals excess risk due to interaction 
(yellow box) divided by risk in the common reference group with none of the risk 
factors (blue box, overweight as young and never HT) 
 
Abbreviations: CI = confidence interval; HT = menopausal hormone therapy 
Overweight as young: Participants reporting weighing above average at 7 and/or 15 
years of age, regardless of baseline BMI 
Remained at normal weight: Participants reporting weighing below the average or 
average at 7 and 15 years of age and having BMI <25 kg/m2 at baseline 
